Achieved three major catalysts to drive future growth: Launched the pediatric indication of Afrezza ® following FDA approval FUROSCIX ReadyFlow™ autoinjector approved for treatment...
Achieved three major catalysts to drive future growth: Launched the pediatric indication of Afrezza® following FDA approvalFUROSCIX ReadyFlow™...
Barchart Research What to Expect from MNKD Earnings MNKD Generated August 4, 2026 Current Price $3.96 EPS Estimate $$-0.02 Consensus Rating Moderate Buy Average Move 7.97% MannKind's Pipeline Enthusiasm...
MNKD Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety & Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF...
Generally well-tolerated with no serious adverse events, bronchospasm or diarrhea; no study drug discontinuations 90% of patients had no [60%] or mild [30%] cough ~450 total inhalations administered...
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , today announced that the Company will report second quarter 2026 financial results...
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced that the Company will report second quarter 2026 financial results...
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 24, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a biopharmaceutical company dedicated to transforming chronic disease care through...
MannKind Announces $50 Million Private Placement ...